医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WNS Positioned in the ‘Winner’s Circle’ in the HfS Blueprint Report for Pharmaceuticals Industry-specific BPO

2016年02月15日 PM10:00
このエントリーをはてなブックマークに追加


 

NEW YORK & MUMBAI, India

WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) services, today announced that it has been positioned in the ‘Winner’s Circle’ in the HfS Blueprint Report for Pharmaceuticals Industry-specific BPO. WNS was cited for its capabilities across both execution and innovation, including account management, delivery performance, generating actionable data, vision for Pharma “As-a-Service,” creating “Intelligent Engagements” focused on business outcomes, and investing in digital solutions.

“WNS is thrilled to be recognized as a ‘Winner’ in the categories of execution and innovation by HfS. Our deep domain expertise, collaborative approach and analytics capabilities have been instrumental in driving our strategic positioning in the Pharma industry. This recognition is a testimony to the investments we have been making in future ready technologies and talent,” said Keshav R. Murugesh, Group CEO, WNS.

WNS combines industry best practices and proprietary tools and methodologies to improve end-client satisfaction and reduce operational costs, while streamlining processes through continuous improvements and technology optimization. WNS has over 2,000 professionals with backgrounds in Pharma and Healthcare, including pharmacists, doctors, certified clinical specialists, researchers and analytics professionals.

This HfS Research Blueprint: Pharmaceuticals Industry-Specific BPO Blueprint, looks at the evolution of Pharma BPO to “As-a-Service”—a market that is increasingly agile, collaborative, and consumer-centric. HfS considers this transition in outsourcing a move to the As-a-Service Economy, placing increasing value on diverse talent, analytics, and collaboration, as well as increasingly on platform-based services. The report includes a comparative analysis of the innovation and execution capabilities of service providers in this market. The service providers in scope are multi-national, multi-functional service providers with industry-specific pharmaceuticals business process support capability in their portfolio.

About WNS

WNS (Holdings) Limited (NYSE: WNS) is a leading global business process management company. WNS offers business value to 200+ global clients by combining operational excellence with deep domain expertise in key industry verticals including Travel, Insurance, Banking and Financial Services, Manufacturing, Retail and Consumer Packaged Goods, Shipping and Logistics, Healthcare and Utilities. WNS delivers an entire spectrum of business process management services such as finance and accounting, customer care, technology solutions, research and analytics and industry specific back office and front office processes. As of December 31, 2015, WNS had 31,340 professionals across 39 delivery centers worldwide including China, Costa Rica, India, Philippines, Poland, Romania, South Africa, Sri Lanka, United Kingdom and the United States. For more information, visit www.wns.com.

Safe Harbor Provision

This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160215005236/en/

CONTACT

WNS (Holdings) Limited
Investors:
David
Mackey

Corporate SVP – Finance & Head of Investor Relations
+1
(201) 942-6261
david.mackey@wns.com
or
Media:
Archana
Raghuram

Head – Corporate Communications
+91 (22) 4095 2397
archana.raghuram@wns.com;
pr@wns.com

同じカテゴリーの記事 

  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告